Search

Displaying results 4471 - 4480 of 10000 in total
  1. Drug

    Larix sibirica wood

    go.drugbank.com/drugs/DB14289
    ApprovedWithdrawn

    Larix sibirica wood is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  2. Drug

    Azadirachta indica leaf

    go.drugbank.com/drugs/DB14352
    Approved

    Azadirachta indica leaf is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  3. Drug

    HGTV-43

    go.drugbank.com/drugs/DB05807
    Experimental

    HGTV43 is an anti-sense treatment designed to produce T cells that are genetically resistant to HIV infection. … HGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company Enzo Biochem, Inc.

  4. Drug

    Washed Microbiota Transplantation

    go.drugbank.com/drugs/DB15745
    Investigational

    The resulting suspension is shown to decrease FMT-related adverse events. … Fecal microbiota transplantation (FMT) is effective in enhancing the gut microbiota of patients experiencing a high range of disease states, including Clostridioides difficile (C. diff) infection, Crohn

  5. Drug

    Opaganib

    go.drugbank.com/drugs/DB12764
    Investigational

    Opaganib, also known as ABC294640, is a selective [sphingosine kinase-2 (SK2)](https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered. … [L27436] This drug has potential anticancer, anti-inflammatory, and antiviral activities, with potential applications in oncology, inflammation, the gastrointestinal system, and COVID-19.

  6. Drug

    OSI-461

    go.drugbank.com/drugs/DB05415
    Investigational

    OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).

  7. Drug

    GW 468816

    go.drugbank.com/drugs/DB05417
    Investigational

    GW 468816 is glycine receptor antagonist. It is designed to aid abstinence in people who have just quit smoking, delaying the time to relapse. It was undergoing phase II trials since December 2003.

  8. Drug

    FavId

    go.drugbank.com/drugs/DB05249
    Investigational

    FavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.

  9. Drug

    AVR118

    go.drugbank.com/drugs/DB04979
    Investigational

    AVR118 is being studied for the promise shown in its ability to mitigate the toxic side effects of other drugs (including those used to treat HIV infection and chemotherapeutic drugs employed in the treatment … for its ability to stimulate the immune system to attack tumor cells (especially those cancer cells that have been damaged by chemotherapeutic agents) and for its ability to treat cachexia (wasting) in

  10. Drug

    Citatuzumab Bogatox

    go.drugbank.com/drugs/DB06072
    Investigational

    VB6-845 is a humanized antibody fragment targeting EpCAM fused with the deimmunized form of the cytotoxin Bouganin and is designed for systemic use against metastatic cancer. … VB6-845 has demonstrated effective cancer cell killing properties in pre-clinical tests.